I strongly disagree but respect your opinion. Time will tell.
I see your point with the OTCs and taking extra but supplement industry is diff. Let’s leave that beast alone until ITC news.
In terms of 0 percent chance they’ll need an outcomes , I would say it’s higher. The problem is if they get labels for TG> 500, even if they don’t get a label for TG under 500 they can steal some market share there based on epa blood level data. If a physician is approached and says reduce it reduced events 25 percent. We have a drug that has better blood levels of the component (epa) Amrn claims was mechanistically likely to have caused such profound anti inflammatory effects, then physicians can prescribe it without CVOT. It’s going to come down to marketing and sales force and whether these small companies team up with BP or not.
One other point, if we get priority review (which we should and I think it’s crazy JT keeps saying he is expecting standard review ), we should be able to get the label quickly and market fast. Our execution is key. Your sales estimates are key. Point being, we need an estimate of sales in 2020.m to really shoot this stock. That projection will be the rocket in the stock price. I’m hoping we can hit > 500 mil this year. Then JT can get early label and give us a massive projection for next year that has to be > billion hopefully more so we can get the ball rolling and explode.
News 
Market Data 
Discover 
AI
